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Long-term effect of inhaled colomycin on exercise capacity in adult 
patients with cystic fibrosis 
G. Perpati 1, E. Pouliou 1, E. Stefanat ou 1, V. Dionysopoulou 1, E. Armeniakou 1, S. 
Papakostopoulos 1, E. Christodoulou 2, A. Papamichalopoulos 2, S. Nanas 2, Ch. 
Roussos 2
~Cystic fibrosis Outpatient Clinic, Athens Chest Hospital, 2Department of 
Pulmonary and OiticaI Care Medicine, National arm Kapodistrian Univemit£ 
Athens, Greece 
INTRODUfiq' ION: Exercise capacity ha cystic fibrosis (CF) patients depends on 
infection control. 
AIM: The aim of this study was to explore the effect of colomycin on exercise 
capacity and clinical status ha adult patients with CF. 
PATIENTS MEqTIODS: Fourteen patients with CF (6 male aged 21.1+12, and 8 
female aged 24+8 ) were studied. They had FEVI~45+33% pred. and SS 55+14. 
Al l  patients were ha stable state treated with rbDNAse and inhaled tobramycin ha 
repeated cycles of 28 days on drug and 28 off drug. Patients underwent a CPET on 
a treadmil l  before and after treatment with colomycin (2CO20)0 IU x 2 id for 6 
months). Colomycin was given to patients on months they didn't receive 
tobramycin. Peak oxygen consumption (VO~ peak) during CPET and at early 
recovery (VO~ It slope) were estimated. 
RESULTS: Statistical analysis howed improve ha SS (59.2 + 9 before vs 68.3+11.7 
after treatment, p<0.~)2), in VO2peak (18.3+5.7 vs 19,2+8.1, p<0.~)2) and VO2/t 
slope (0.41+0.2 vs 0.48+ 0.31, p<0,~)7 ). 
CONCLUSION: hahaled Colomycin added to conventional therapy in adult patients 
with CF improves clinical status and exercise capacity. 
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Experiences from 15 years use of inhaled colisSn in b'eatment of 
I~ aeruginosa in a CF-clinic 
C.R. Hansen 1, T. Pressler 2, N. HNby 1 
CF-Centre, Departments of iMicrobioIogy arld 2paediatrics, Rigshospitalet, 
Copenhagen, Der~nadr 
Aim/melhod:  Since 1989, intermittent colonization wi th /~ aeruginosa has been 
treated with inhaled colistin and oral cipr ofloxacin. The aim of this study is to assess 
the effect of this treatment strategy on the cecurrence of PA strains resistant o 
colistin. A population of CF patients without cbr onic PA infection were followed for 
15 years. 146 patients were included. 
Results: Median age at t ime of diagnosis of CF was 0.5 years (range 0 12). The 
study period includes 1871 patient years. Intermittently colonized patients had a 
median number of 5 (range 1 46) sputum samples with growth of PA, resulting in 
a total number of 1052 treatments. Treatment length changed during the study 
period from initially 3 weeks courses to, ha the late 1990"s, 3 months courses. 39 
patients (27%) developed cbronic PA infection. Median age at onset of cbronic 
infection was 14.5 years (range 3.6 28.3). Al l  chronically infected patients have 
been treated with inhaled colistin continuously. 
We investigated 1052 sputum samples positive for PA, collected from intermittently 
colonized patients, and 3870 sputum samples positive for PA from chronically 
infected patients. Among cbronically infected patients, only 4 patients (14 sputum 
samples) had growth of colistin resistant strains of PA at some time. (0.4% of strains 
from cbr onically infected patients, 0.3% of all isolated strains). These patients had 
been cbronically infected for 2, 4, 8 mad 9 years, respectively. No intermittently 
colonized patients had growth of colistin resistant strains. 
Conclusion: O1" 146 patients with intermittent/~ aeruginosa infection, 39 became 
cbronically infected during a study period of 15 years. 4 cbronically infected 
patients had transient colonization with colistin resistant strains. 
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1OYears of Colistin use in a Regional Cystic Fibrosis Centre 
I. Clifton 1, M. Denton 9, C. Etheringt on 1, D. Pecldaam 1,S. Conway 1 
iRegionaI Adult Cystic Fibrosis Centre, Seacroft Hopsital, 2Dept of Microbiolog3~ 
Leeds General Infirmary 
Ahats The aim of this study was to see i f  the wide spread use of intravenoas (IV) 
colistin over a ten year period had resulted in ma increase ha the prevalence of colistin 
resistant isolates of Psendomonas aeruginosa 0PA) ha patients with cystic fibrosis (CF). 
Methods Data including the number of IV courses, matibiotics administered mad PA 
antibiotic resistance w re collected from the regional CF unit and microbiology 
databases between 1st Jma 1995 mad 31st Dec 2004. Prior to 2000, antibiotic 
resistance testing was undertaken using a standardized disk diffusion technique, 
after this date the Stokes comparative disc diffusion method was used. 
Results 
% patients with colistin Number of IV cohsitin 
resistant PA isolate comses (Total IV corn ses) 
1995 013% 213 (361) 
1996 004% 211 (445) 
1997 093% 940 (481) 
1998 074% 973 (474) 
1999 168% 365 (593) 
2000 017% 306 (585) 
2001 036% 297 (579) 
2002 012% 306 (605) 
2003 041% 174 (344) 
2004 103% 230 (544) 
Over the ten year study period, a mean of 0.70% and 0.42% patients before and after 
the year 2 (~)  had a colistin resistant isolate of PA respectively. A mean of 477.7 IV 
antibiotic ourses were administered annually. The mean number of IV course of 
colistin administered was 255.6 per year. Using linear regression the rate of increase 
ha colistin resistance was 0.38% per year from 1995 unti l  1999. Prom the year 2(~),  
the rate of increase was 0.18% per annum. 
Conclusions Direct comparison of resistance data before and after the year 2 (~)  
can not be made as two different laboratory techniques were used to assess 
resistance. However our results show that despite the frequent use of IV colistin, 
there has been l ittle change ha the prevalence of colistin resistance among isolates 
of PA over a ten year period. 
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In-vib'o based comparison of deposition efficiency of two inhalation 
systems for inhalaSon of Colistin 
B. Mfi l l inger 1, I% Brand 2, O. Pechtold 9, K. Sommerer 2, G. Scheuch 1
llnamed GmbH, 35285 Gemi~nder~ 21named Research GmbH & Co. KG 82131 
Gauting, Germany 
Inhalation of Colistin is ma important intervention i  the therapy of patients with 
cystic fibrosis. In order to improve inhalation of Colistin (3ml, Griinenthal), this in 
vitro study was performed with a conventional nebulizer 0Pari Turbo B oy N/Pari LC 
Plus) and ma inhalation system that controls the breathing pattern during inspiration 
(AKITA/Pari LC Star). 
In this study, two different echniques mad devices to administer inhaled Colistin 
were compared. The first device is conventionally used for Colisiin inhalation (Pari 
LC Plus ® with Pari Turbo Boy N ® compressor), whi le  the second device uses a jet  
nebulizer 0Pari LC Star e) in combination with ma "intell igent" compressor (Aldt a ®) 
to control the breathing pattem. Emitted dose and particle size were measured and 
used to estimate lung deposition using the ICRP lung deposition model. The t ime 
necessary to deposit a f ixed amount of drug in the lung was also evaluated. 
Results: In vitro measurements and deposition calculations. 
Time for Maximum 
Emitted depositing 0.46 ml Deposition 
MMD Doze within the lungs within the lungs 
Nebufizer System [gm] [ml] [nfin] [ml] 
LC PLUS + TURBO BOY 3.60 32.6 6.1 0.46 
LC STAR +ANITA 2.82 63.9 4.2 1.63 
In this in vitro study is has been shown that the inhalation of Colistin using 
controlled breathing pattern with the AKITA® system results in more efficient drug 
delivery compared to the conventional inhalation system PARI Turbo Boy N® / LC 
Plus®. Using the AKITA ® device, drug nebulization only takes place during the 
inspiration period whereas with the conventional device, nebulization is continuous, 
resulting in a considerable drug loss during the xpiration phase. Second, the 
AKITA ® device uses a controlled eep and slow inhalation pattern. 
